Game-Changing Cancer Detection Technology: RNAscope Shows Superior Results in Multiple Tumors

TransCode Therapeutics, Inc. Announces Registered Direct Offering…
DBV Technologies Secures Agreement with FDA on Safety Exposure Da…
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI…
UNITY Biotechnology Announces Topline Results from the ASPIRE Pha…
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeh…
U Power Limited (Nasdaq: UCAR) Announces Landmark Joint Venture w…
TransCode Therapeutics, Inc. Announces Registered Direct Offering…
DBV Technologies Secures Agreement with FDA on Safety Exposure Da…
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI…
UNITY Biotechnology Announces Topline Results from the ASPIRE Pha…
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeh…
U Power Limited (Nasdaq: UCAR) Announces Landmark Joint Venture w…
Bio-Techne (NASDAQ: TECH) announced advancements in its RNAscope technology for biomarker detection and pathology laboratory workflow improvements, to be presented at the 2025 USCAP Annual Meeting in Boston (March 22-27). The company’s Advanced Cell Diagnostics brand will showcase the technology at booth #222.
During the ‘RNAscope: Lightning Lunch and Learn’ session on March 25, four leading pathologists will present their research:
The presentations will demonstrate RNAscope’s potential to improve performance over existing methods and reduce time to results in detecting clinically relevant biomarkers, including secreted proteins, point mutations, and chromosomal translocations.
Bio-Techne (NASDAQ: TECH) ha annunciato progressi nella sua tecnologia RNAscope per la rilevazione di biomarcatori e il miglioramento del flusso di lavoro nei laboratori di patologia, che saranno presentati al Congresso Annuale USCAP 2025 a Boston (22-27 marzo). Il marchio Advanced Cell Diagnostics dell’azienda mostrerà la tecnologia allo stand n. 222.
Durante la sessione ‘RNAscope: Lightning Lunch and Learn’ del 25 marzo, quattro importanti patologi presenteranno le loro ricerche:
Le presentazioni dimostreranno il potenziale di RNAscope di migliorare le prestazioni rispetto ai metodi esistenti e di ridurre i tempi per i risultati nella rilevazione di biomarcatori clinicamente rilevanti, inclusi proteine secrete, mutazioni puntiformi e traslocazioni cromosomiche.
Bio-Techne (NASDAQ: TECH) anunció avances en su tecnología RNAscope para la detección de biomarcadores y mejoras en el flujo de trabajo de los laboratorios de patología, que se presentarán en la Reunión Anual USCAP 2025 en Boston (22-27 de marzo). La marca Advanced Cell Diagnostics de la compañía mostrará la tecnología en el stand n.º 222.
Durante la sesión ‘RNAscope: Lightning Lunch and Learn’ el 25 de marzo, cuatro patólogos destacados presentarán sus investigaciones:
Las presentaciones demostrarán el potencial de RNAscope para mejorar el rendimiento en comparación con los métodos existentes y reducir el tiempo para obtener resultados en la detección de biomarcadores clínicamente relevantes, incluidos proteínas secretadas, mutaciones puntuales y translocaciones cromosómicas.
Bio-Techne (NASDAQ: TECH)는 바이오마커 탐지 및 병리 실험실 작업 흐름 개선을 위한 RNAscope 기술의 발전을 발표했으며, 이는 2025년 USCAP 연례 회의에서 보스턴(3월 22-27)에서 발표될 예정입니다. 회사의 Advanced Cell Diagnostics 브랜드는 부스 #222에서 이 기술을 선보일 것입니다.
3월 25일 ‘RNAscope: Lightning Lunch and Learn’ 세션 동안, 네 명의 저명한 병리학자들이 그들의 연구를 발표할 것입니다:
이 발표들은 RNAscope가 기존 방법보다 성능을 개선하고 임상적으로 관련된 바이오마커, 즉 분비 단백질, 점 돌연변이 및 염색체 전위 탐지에서 결과 도출 시간을 단축할 수 있는 잠재력을 보여줄 것입니다.
Bio-Techne (NASDAQ: TECH) a annoncé des avancées dans sa technologie RNAscope pour la détection de biomarqueurs et l’amélioration des flux de travail en laboratoire de pathologie, qui seront présentées lors de la réunion annuelle USCAP 2025 à Boston (22-27 mars). La marque Advanced Cell Diagnostics de l’entreprise mettra en avant la technologie au stand n° 222.
Lors de la session ‘RNAscope: Lightning Lunch and Learn’ le 25 mars, quatre pathologistes de premier plan présenteront leurs recherches :
Les présentations démontreront le potentiel de RNAscope à améliorer les performances par rapport aux méthodes existantes et à réduire le temps de résultats dans la détection de biomarqueurs cliniquement pertinents, y compris les protéines sécrétées, les mutations ponctuelles et les translocations chromosomiques.
Bio-Techne (NASDAQ: TECH) hat Fortschritte in seiner RNAscope-Technologie zur Biomarkererkennung und zur Verbesserung des Arbeitsablaufs in Pathologielaboren angekündigt, die auf dem USCAP-Jahrestreffen 2025 in Boston (22.-27. März) präsentiert werden. Die Marke Advanced Cell Diagnostics des Unternehmens wird die Technologie am Stand Nr. 222 vorstellen.
Während der Sitzung ‘RNAscope: Lightning Lunch and Learn’ am 25. März werden vier führende Pathologen ihre Forschung präsentieren:
Die Präsentationen werden das Potenzial von RNAscope demonstrieren, die Leistung im Vergleich zu bestehenden Methoden zu verbessern und die Zeit bis zu den Ergebnissen bei der Erkennung klinisch relevanter Biomarker, einschließlich sekretierter Proteine, Punktmutationen und chromosomaler Translokationen, zu verkürzen.
MINNEAPOLIS, March 24, 2025 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will be exhibiting and showcasing RNAscope technology at booth #222.
Leading pathologists will describe how they have used RNAscope technology to detect clinically relevant biomarkers, including secreted proteins, point mutations and chromosomal translocations, with the potential to improve performance over existing methods and reduce time to results. The session “RNAscope: Lightning Lunch and Learn” at noon on Tuesday, March 25, will highlight four pathologists describing their work using RNAscope technology:
“We’ve made exciting advancements on in situ hybridization methods enabling novel applications in pathology laboratories,” commented Dr. Matt McManus, President of Bio-Techne’s Diagnostics and Spatial Biology Segment. “This conference session highlights the frontier of clinical and translational research by leading pathologists using the latest RNAscope technologies for detecting the molecular underpinnings of disease.”
For Research Use Only. Not intended for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-advances-in-the-detection-of-clinically-relevant-biomarkers-using-rnascope-technologies-at-the-2025-uscap-annual-meeting-302407635.html
SOURCE Bio-Techne Corporation
© 2020-2025 StockTitan.net
Please enter your login and password
Forgot password?
Don’t have an account? Sign Up!
Please enter your email address
To create a free account, please fill out the form below.
Already have an account? Login